The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

AMD’s RDNA 4 graphics cards (also referred to as the Radeon RX 8000 series) are already on the horizon, but they’re still a bit of a mystery. Fortunately, various leakers break up that silence ...

In some cases, they paid physicians to fraudulently stamp prescription forms when they had not seen patients. In others, they used physicians’ stamps without their knowledge. Initially ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...

We list the best online form builders, to make building forms simple and easy in order to collect customer feedback and marketing data. If you are looking for a simple, fast, and easy way to ...

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise ...

(2) MOUNTAIN HIGH has been costly to follow but can still win. (9) WHISTLING STRAIT is worth a market check. (3) SUNFIRE has the form and experience to make her presence felt. (11) PINK PIGEON has ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Meanwhile, the company's Pharma segment generated €8.3B in sales with ~10% YoY growth as Dupixent sales rose ~22% YoY to €3.4B, prompting the company to reaffirm its €13B full-year sales ...